{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:15:39Z","timestamp":1790846139775,"version":"4.1.0"},"reference-count":33,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,2,16]]},"DOI":"10.1182\/blood-2016-11-731604","type":"journal-article","created":{"date-parts":[[2016,12,29]],"date-time":"2016-12-29T02:50:56Z","timestamp":1482979856000},"page":"832-837","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":87,"title":["Does ruxolitinib prolong the survival of patients with myelofibrosis?"],"prefix":"10.1182","volume":"129","author":[{"given":"Francisco","family":"Cervantes","sequence":"first","affiliation":[{"name":"Hematology Department, Hospital Cl\u00ednic, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer, University of Barcelona, Barcelona, Spain; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Pereira","sequence":"additional","affiliation":[{"name":"Hemotherapy Department, Hospital Cl\u00ednic, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"13","key":"2019111903585898300_B1","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2019111903585898300_B2","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.leukres.2006.12.002","article-title":"Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT)","volume":"31","author":"Mesa","year":"2007","journal-title":"Leuk Res"},{"issue":"2","key":"2019111903585898300_B3","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s12185-012-1235-2","article-title":"Genetic and epigenetic alterations of myeloproliferative disorders","volume":"97","author":"Milosevic","year":"2013","journal-title":"Int J Hematol"},{"issue":"17","key":"2019111903585898300_B4","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2014-07-575373","article-title":"How I treat myelofibrosis","volume":"124","author":"Cervantes","year":"2014","journal-title":"Blood"},{"issue":"24","key":"2019111903585898300_B5","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.2012.42.0240","article-title":"Improving survival trends in primary myelofibrosis: an international study","volume":"30","author":"Cervantes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111903585898300_B6","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111903585898300_B7","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111903585898300_B8","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111903585898300_B9","first-page":"CD010298","article-title":"Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis","author":"Mart\u00ed-Carvajal","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2019111903585898300_B10","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.2147\/OTT.S31916","article-title":"Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis","volume":"8","author":"Barosi","year":"2015","journal-title":"Onco Targets Ther"},{"key":"2019111903585898300_B11","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"4","key":"2019111903585898300_B12","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"2019111903585898300_B13","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","article-title":"GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"2019111903585898300_B14","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3324\/haematol.2014.119545","article-title":"A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase 3 trials of ruxolitinib for the treatment of myelofibrosis","volume":"100","author":"Vannucchi","year":"2015","journal-title":"Haematologica"},{"issue":"12","key":"2019111903585898300_B15","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.3324\/haematol.2013.092155","article-title":"Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I","volume":"98","author":"Verstovsek","year":"2013","journal-title":"Haematologica"},{"issue":"4","key":"2019111903585898300_B16","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3324\/haematol.2014.115840","article-title":"Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I","volume":"100","author":"Verstovsek","year":"2015","journal-title":"Haematologica"},{"issue":"25","key":"2019111903585898300_B17","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","article-title":"Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis","volume":"122","author":"Cervantes","year":"2013","journal-title":"Blood"},{"issue":"8","key":"2019111903585898300_B18","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/leu.2016.148","article-title":"Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis","volume":"30","author":"Harrison","year":"2016","journal-title":"Leukemia"},{"issue":"6","key":"2019111903585898300_B19","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1080\/10543406.2011.592233","article-title":"Correcting overall survival for the impact of crossover via a rank-preserving structural failure time (RPSFT) model in the RECORD-1 trial of everolimus in metastatic renal-cell carcinoma","volume":"22","author":"Korhonen","year":"2012","journal-title":"J Biopharm Stat"},{"issue":"4","key":"2019111903585898300_B20","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1001\/jama.289.4.454","article-title":"Scope and impact of financial conflicts of interest in biomedical research: a systematic review","volume":"289","author":"Bekelman","year":"2003","journal-title":"JAMA"},{"key":"2019111903585898300_B21","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1146\/annurev.publhealth.18.1.83","article-title":"Censoring issues in survival analysis","volume":"18","author":"Leung","year":"1997","journal-title":"Annu Rev Public Health"},{"key":"2019111903585898300_B22","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1186\/1745-6215-15-456","article-title":"Reducing bias in open-label trials where blinded outcome assessment is not feasible: strategies from two randomised trials","volume":"15","author":"Kahan","year":"2014","journal-title":"Trials"},{"issue":"8","key":"2019111903585898300_B23","doi-asserted-by":"crossref","first-page":"560","DOI":"10.7326\/0003-4819-159-8-201310150-00709","article-title":"Randomized trials analyzed as observational studies","volume":"159","author":"Hern\u00e1n","year":"2013","journal-title":"Ann Intern Med"},{"issue":"14","key":"2019111903585898300_B24","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1182\/blood-2013-11-536557","article-title":"Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study","volume":"123","author":"Guglielmelli","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2019111903585898300_B25","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood-2015-03-633404","article-title":"Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib","volume":"126","author":"Patel","year":"2015","journal-title":"Blood"},{"issue":"15","key":"2019111903585898300_B26","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1056\/NEJMc1109555","article-title":"Long-term outcome of treatment with ruxolitinib in myelofibrosis","volume":"365","author":"Tefferi","year":"2011","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111903585898300_B27","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1182\/blood-2012-02-414631","article-title":"Long-term outcomes of 107 patients with myelofibrosis receiving JAK1\/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls","volume":"120","author":"Verstovsek","year":"2012","journal-title":"Blood"},{"issue":"12","key":"2019111903585898300_B28","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1182\/blood-2013-12-544411","article-title":"Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts","volume":"123","author":"Passamonti","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2019111903585898300_B29","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"issue":"33","key":"2019111903585898300_B30","doi-asserted-by":"crossref","first-page":"5587","DOI":"10.1200\/JCO.2009.22.8833","article-title":"Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera\/essential thrombocythemia myelofibrosis","volume":"27","author":"Tam","year":"2009","journal-title":"J Clin Oncol"},{"issue":"22","key":"2019111903585898300_B31","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1182\/blood-2009-12-255943","article-title":"Identification during the follow-up of time-dependent prognostic factors for the competing risks of death and blast phase in primary myelofibrosis: a study of 172 patients","volume":"115","author":"Morel","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2019111903585898300_B32","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/bjh.12375","article-title":"Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy","volume":"162","author":"Harrison","year":"2013","journal-title":"Br J Haematol"},{"key":"2019111903585898300_B33","article-title":"Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations","author":"Marchetti","journal-title":"Leukemia"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/7\/832\/1401692\/blood731604.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/129\/7\/832\/1401692\/blood731604.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T23:04:21Z","timestamp":1749855861000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/129\/7\/832\/36181\/Does-ruxolitinib-prolong-the-survival-of-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,16]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,2,16]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2016-11-731604","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,16]]}}}